-
Seelos's Amyotrophic Lateral Sclerosis Candidate, SLS-005 An Orphan Drug In Europe
Thursday, May 27, 2021 - 8:28am | 120Read More...Seelos Therapeutics Inc's (NASDAQ: SEEL) Trehalose (SLS-005) has received Orphan Drug Designation for amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Under the orphan designation, Seelos stands to...
-
Tiziana Life Starts Testing Nasally Administered Foralumab in Multiple Sclerosis Patients
Tuesday, May 25, 2021 - 6:16am | 288Read More...Under an individual patient expanded access program, Tiziana Life Sciences plc (NASDAQ: TLSA) has dosed the first patient with secondary progressive multiple sclerosis with nasally administered foralumab. Nasal Foralumab 50 mcg (25 mcg/nostril) will be administered in 3-week...
-
Janssen's Multiple Sclerosis Treatment Scores European Approval
Monday, May 24, 2021 - 12:49pm | 160Read More...The European Commission has approved Janssen's, a unit of Johnson & Johnson (NYSE: JNJ) Ponvory (ponesimod), to treat adult patients with relapsing multiple sclerosis. The EC approval of ponesimod is based on data from the Phase 3 OPTIMUM trial that met the primary endpoint...
-
Aeterna Zentaris Starts Animal Studies For Macimorelin For Amyotrophic Lateral Sclerosis
Monday, May 17, 2021 - 10:12am | 256Read More...Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease). The preclinical development program is...
-
Orphazyme Shares Plummet As Arimoclomol Flunks In Amyotrophic Lateral Sclerosis Study
Friday, May 7, 2021 - 10:02am | 279Read More...Orphazyme A/S (NASDAQ: ORPH) has announced that the ORARIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints. No important safety signals were reported in the trial. Topline data will be presented at the...
-
Tiziana To Treat Multiple Sclerosis Patient With Nasal Administration of Foralumab
Tuesday, March 30, 2021 - 11:04am | 267Read More...The FDA has allowed evaluation of Tiziana Life Sciences Plc's (NASDAQ: TLSA) nasal administration with foralumab in a secondary progressive multiple sclerosis (SPMS) patient at the Brigham and Women's Hospital (BWH), Harvard University. The patient will be treated...
-
Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis
Tuesday, March 30, 2021 - 7:03am | 207Read More...Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis. The company is developing and marketing the product under a license...
-
BrainStorm Cell Stock Surges As NurOwn Aces Mid-Stage Multiple Sclerosis Study
Wednesday, March 24, 2021 - 7:46am | 344Read More...BrainStorm Cell Therapeutics Inc (NASDAQ: BCLI) has reported topline Phase 2 data evaluating three repeated administrations of NurOwn (MSC-NTF cells), each given two months apart, as a treatment for progressive multiple sclerosis (MS). The study achieved the primary endpoint of...
-
Janssen's Ponvory Wins FDA Nod For Relapsing Multiple Sclerosis
Friday, March 19, 2021 - 9:31am | 219Read More...The FDA has approved Janssen's a unit of Johnson & Johnson (NYSE: JNJ) Ponvory (ponesimod) for relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Ponvory is a...
-
Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis Studies
Thursday, February 25, 2021 - 12:38pm | 310Read More...Clene Inc (NASDAQ: CLNN) has reported updated blinded interim data from the VISIONARY-MS Phase 2 study evaluating the efficacy and safety of lead drug candidate, CNM-Au8, in multiple sclerosis. The analyses compare changes in functional composite scores over the study...
-
Provention Bio's CEO On Identifying Autoimmune Diseases 'Before It's Too Late'
Tuesday, May 5, 2020 - 11:28am | 953Read More...When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention. These diseases can silently do irreversible damage, according to Provention Bio Inc (NASDAQ: PRVB) CEO...
-
FDA Approves Novartis Drug To Treat More Severe Form Of Multiple Sclerosis
Wednesday, March 27, 2019 - 9:15am | 369Read More...Culminating a month that saw mostly favorable FDA verdicts, Novartis AG (NYSE: NVS) announced regulatory approval for its multiple sclerosis drug. What Happened Swiss pharma giant Novartis announced Tuesday evening the FDA greenlighted its oral drug to treat adults with relapsing forms of multiple...
-
Sangamo Announces TxCell Acquisition, Patient Dosing In SB-318
Monday, July 23, 2018 - 11:35am | 393Read More...Sangamo Therapeutics Inc (NASDAQ: SGMO) announced Monday it would acquire TxCell for about €72 million to complement its ex vivo gene editing program. In conjunction with the news, management reported treatment initiation for its first patient in a Phase 1/2 study of SB-318 for...
-
UBS: Buy Biogen For Pipeline, M&A Potential
Wednesday, January 31, 2018 - 10:29am | 377Read More...Some on the Street consider Biogen Inc (NASDAQ: BIIB)’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside. The Rating UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410. The Thesis Biogen’s...
-
Momenta Pharma Could Face Pressure Following Approval Of Mylan's Generic Copaxone
Thursday, October 5, 2017 - 8:58am | 435Read More...The U.S. Food and Drug Administration's approval of Mylan N.V. (NASDAQ: MYL)'s generic version of Copaxone for the treatment of relapsing multiple sclerosis should be seen as a "clear negative" for Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)'s Glatopa franchise, analysts at Baird said. The firm's...
